S
Stefanie Sawall
Researcher at University of Hamburg
Publications - 10
Citations - 267
Stefanie Sawall is an academic researcher from University of Hamburg. The author has contributed to research in topics: Cancer & GAS6. The author has an hindex of 3, co-authored 7 publications receiving 221 citations.
Papers
More filters
Journal ArticleDOI
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Isabel Ben-Batalla,Alexander Schultze,Mark Wroblewski,Robert Erdmann,Michael Heuser,Jonas S. Waizenegger,Kristoffer Riecken,Mascha Binder,Denis M. Schewe,Stefanie Sawall,Victoria Witzke,Miguel Cubas-Cordova,Melanie Janning,Jasmin Wellbrock,Boris Fehse,Christian Hagel,Jürgen Krauter,Arnold Ganser,James B. Lorens,Walter Fiedler,Peter Carmeliet,Klaus Pantel,Carsten Bokemeyer,Sonja Loges +23 more
TL;DR: Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML and might represent a novel therapeutic avenue for AML.
Journal ArticleDOI
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Jonas S. Waizenegger,Isabel Ben-Batalla,Niels Weinhold,Tobias Meissner,Mark Wroblewski,Melanie Janning,Kristoffer Riecken,Manfred Binder,Djordje Atanackovic,H. Taipaleenmaeki,Denis M. Schewe,Stefanie Sawall,Victoria Gensch,Miguel Cubas-Cordova,Anja Seckinger,Walter Fiedler,Eric Hesse,N Kröger,Boris Fehse,Dirk Hose,Bernard Klein,Marc-Steffen Raab,Klaus Pantel,Carsten Bokemeyer,Sonja Loges +24 more
TL;DR: The Gas6-Mer axis represents a novel candidate for therapeutic intervention in this incurable malignancy and inhibition of the Gas6 receptor Mer or therapeutic targeting of Gas6 by warfarin reduced myeloma burden and improved survival in a systemic model ofMyeloma.
Journal ArticleDOI
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Isabel Ben-Batalla,Miguel Cubas-Cordova,Florian Udonta,Mark Wroblewski,Jonas S. Waizenegger,Melanie Janning,Stefanie Sawall,Victoria Gensch,Lin Zhao,Inigo Martinez-Zubiaurre,Kristoffer Riecken,Boris Fehse,Klaus Pantel,Carsten Bokemeyer,Sonja Loges +14 more
TL;DR: Cox-2 inhibition can increase efficacy of anti-angiogenic treatments and the findings might pave the road for clinical investigations of concomitant blockade of Cox-2 and VEGF-signaling.
Journal ArticleDOI
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
Thomas Walle,Sunanjay Bajaj,Joscha A. Kraske,T. Rösner,Christiane S Cussigh,Katharina A. Kälber,L. J. Müller,S.B. Strobel,Jana Burghaus,Stefan M. Kallenberger,Christoph Stein-Thöringer,Maximilian Jenzer,Antonia Schubert,Steffen Kahle,Anja Williams,Birgit Hoyler,Lin Zielske,Renate Skatula,Stefanie Sawall,Mathias F. Leber,Russell Kunes,Johannes Krisam,Carlo Fremd,Andreas Schneeweiss,Jürgen Krauss,Leonidas Apostolidis,Anne Berger,Georg Martin Haag,Stefanie Zschäbitz,Niels Halama,Christoph Springfeld,Jessica C. Hassel,Dirk Jäger,Omar Abdelrahim,Elena Busch,Patrick Derigs,Katharina Dischinger,Fouad Mitri,Kerstin Schmidt,Irfan A. Bhatti,Barbara Grün,Nicolas Hohmann,Lena Woydack,Xin-Wen Zhang,Dyke Ferber,Andreas Mock,Tillmann Pompecki,Timo Schank,Guy Ungerechts +48 more
TL;DR: In this paper , adverse events and serum cytokines in patients with 23 different tumors undergoing or not undergoing COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (n = 220).
Journal ArticleDOI
BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
Robert Erdmann,Heather G. Jørgensen,Isabel Ben-Batalla,Nils Kruse,David Micklem,Gunhild von Amsberg,Philippe Schafhausen,Alexander Schultze,Mark Wroblewski,Mascha Binder,Miguel Cubas-Cordova,Tobias Hadlich,Melanie Janning,Stefanie Sawall,Victoria Gensch,Elaine K. Allan,Leena Mukherjee,Heather Morrison,Jennifer Cassells,Nicolaus Kroeger,James B. Lorens,Richard E. Clark,Steffen Koschmieder,Peter Vandenberghe,Tim H. Brümmendorf,Andreas Hochhaus,Peter Carmeliet,Tessa L. Holyoake,Klaus Pantel,Carsten Bokemeyer,Sonja Loges +30 more
TL;DR: BGB324 is a dual inhibitor of BCR-ABL1 and Axl and down regulated its expression in KCL-22 and K562 cells by means of shRNA to confirm Axl as specific therapeutic target and confirm that Axl promotes CML growth.